- Home
- MAIA vs VRCA Comparison
MAIA vs VRCA Comparison
Compare MAIA & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAIA | VRCA |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 32.7M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MAIA | VRCA |
|---|---|---|
| Price | $1.24 | $8.44 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 418.8K | 358.1K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,829,000.00 |
| Revenue This Year | N/A | $332.45 |
| Revenue Next Year | N/A | $12.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 234.73 |
| 52 Week Low | $0.87 | $3.28 |
| 52 Week High | $2.74 | $13.00 |
Technical Indicators
Market Signals| Indicator | MAIA | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 70.06 |
| Support Level | $1.07 | $6.26 |
| Resistance Level | $1.46 | $9.82 |
| Average True Range (ATR) | 0.12 | 0.90 |
| MACD | 0.04 | 0.41 |
| Stochastic Oscillator | 57.63 | 76.27 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.